Eli Lilly Archives | PharmaShots

Eli Lilly’s Cyramza (ramucirumab) Receives FDA’s Approval as a Second-line Treatment in Patients with High AFP Hepatocellular Carcinoma

May 13, 2019May 15, 2019Tuba Khan

Shots: The approval is based on REACH‑2 study (NCT02435433) results assessing Cyramza (ramucirumab) + BSC vs PBO + BSC in 292 advanced HCC [...]

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Two P-III Studies to Treat Low- and High-Frequency Episodic Migraine

May 7, 2019May 10, 2019Tuba Khan

Shots: The P-III EVOLVE-1 and EVOLVE-2 studies result involves assessing of Emgality (galcanezumab-gnlm, 120mg & 240mg) vs PBO in 1,700 patients with low [...]

Eli Lilly Facilitates the Withdrawal of Lartruvo (olaratumab) from the Global Market for Advanced Soft Tissue Sarcoma

April 25, 2019April 26, 2019Tuba Khan

Shots: The withdrawal follows the failure of P-III ANNOUNCE study assessing Lartruvo (olaratumab) + doxorubicin followed by Lartruvo as monothx vs doxorubicin + [...]

Eli Lilly to Sell Rights for its Two Antibiotics and a Manufacturing Facility to Eddingpharm in China for $375M

April 23, 2019April 26, 2019Tuba Khan

Shots: Eli Lilly to receive $75M upfront & $300M on the completion of transaction. Eddingpharm to get exclusive rights for Lilly’s two antibiotics, [...]

Pfizer & Eli Lilly Report Results of Tanezumab in Long-Term P-III Study for Osteoarthritis

April 19, 2019April 24, 2019Tuba Khan

Shots: The P-III A4091058 study involves assessing of Tanezumab (2.5 & 5mg, q8w) vs NSAIDS (naproxen 500 mg/celecoxib 100 mg/diclofenac extended release 75 [...]

Eli Lilly Reports Positive Results of Cyramza (ramucirumab) in P-III RELAY Study for mNSCLC

March 12, 2019April 24, 2019Shiwani Sharma

Shots: The P-III RELAY study involves assessing of Cyramza + erlotinib vs PBO + erlotinib in 449 patients with EGFR mutated mNSCLC across [...]

Eli Lilly Reports Results of Olumiant (baricitinib) in P-III BREEZE-AD1 and BREEZE-AD2 study for Moderate-to-Severe Atopic Dermatitis (AD)

February 5, 2019April 24, 2019Shiwani Sharma

Shots: The two P-III study BREEZE-AD1 and BREEZE-AD2 involves assessing of baricitinib vs PBO in patients with moderate-to-severe AD The two P-III study [...]

Eli Lilly’s Alimta (pemetrexed) + Keytruda (pembrolizumab) Receives FDA’s Expanded Label Approval for 1L Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

January 31, 2019April 24, 2019Shiwani Sharma

Shots: The expanded label approval is based on P-III KEYNOTE-189 study results assessing Alimta + pembrolizumab + Pt-based CT vs Alimta + Pt-based [...]

Pfizer and Eli Lilly Report Results of Tanezumab in P-III OA study (A4091057) for Moderate-To-Severe Osteoarthritis (OA) Pain

January 30, 2019April 24, 2019Shiwani Sharma

Shots: The P-III OA study involves assessing of tanezumab (2.5mg/5mg, SC) vs PBO in 849 patients in the ratio (1:1:1) with moderate-to-severe OA [...]

Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III Study for Advanced or Metastatic Soft Tissue Sarcoma (STS)

January 22, 2019April 25, 2019Shiwani Sharma

Shots: The P-III ANNOUNCE study involves assessing of Lartruvo + doxorubicin following lartruvo monothx vs doxorubicin + PBO following PBO monothx in patients [...]